Pacer Advisors
ATXS

Pacer Advisors’s Astria Therapeutics ATXS Stock Holding History

Pacer Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-613
Closed -$5.58K – 2572
2024
Q2 		$5.58K Sell
613
-119
-16% -$1.16K ﹤0.01% 3626
2024
Q1 		$10.3K Buy
+732
New +$9.12K ﹤0.01% 3531

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pacer Advisors's ATXS Position: Q3 2024 in Review

Pacer Advisors sold out of Astria Therapeutics (ATXS) in Q3 2024, closing a stake of 613 shares — an estimated $5.58K sold.

Pacer Advisors first reported a position in ATXS in Q1 2024 and held it in 2 quarters. The position peaked at $10.3K in Q1 2024. 103 funds tracked by Wall St. Rank hold ATXS as of Q3 2024.

  • Pacer Advisors reported no remaining Astria Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 613 Astria Therapeutics shares in Q3 2024, an estimated $5.58K.
  • Pacer Advisors first reported a position in Astria Therapeutics in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's Astria Therapeutics position peaked at $10.3K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.